Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review

Abstract The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic revie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transfusion medicine reviews 2013-04, Vol.27 (2), p.91-104
Hauptverfasser: Lin, David M, Murphy, Linda S, Tran, Minh-Ha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104
container_issue 2
container_start_page 91
container_title Transfusion medicine reviews
container_volume 27
creator Lin, David M
Murphy, Linda S
Tran, Minh-Ha
description Abstract The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review—in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement—to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non–cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.
doi_str_mv 10.1016/j.tmrv.2013.01.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1326730021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0887796313000035</els_id><sourcerecordid>1326730021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-c6fdfa68b2cd36ac88be663101ef192ce1022f6b684d7bd0e2eeea820158fb9b3</originalsourceid><addsrcrecordid>eNp9kV9rFDEUxYModq1-AR8kj77MmD872YyIUJZWCwWLa59DkrnTZp1J1iSzut--GbYW9KFPF-4958D5XYTeUlJTQsWHbZ3HuK8ZobwmtCaEPUML2nBWtctWPEcLIuWqWrWCn6BXKW2LgEoiXqITxpeCNZws0HSTAIceX8eQ72IYjfN4HcbdAH_K9BZ8jjpDwtp3-MKZ6Hy4Bf_vrXjyHeBriC7soOzcHvAGcnb-9iM-w5tDyjCWtcXfYe_g92v0otdDgjcP8xTdXJz_WH-trr59uVyfXVV22TS5sqLvei2kYbbjQlspDQjBS3noacssUMJYL4yQy25lOgIMALQsQBrZm9bwU_T-mLuL4dcEKavRJQvDoD2EKSnKmVjxmUuRsqPUxpBShF7toht1PChK1IxbbdWMW824FaGquIrp3UP-ZEboHi1_-RbBp6MASsvSPKpkHRR0nYtgs-qCezr_8392OzjvrB5-wgHSNkzRF36KqsQUUZv54fO_aelECG_4PV5yqEM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1326730021</pqid></control><display><type>article</type><title>Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lin, David M ; Murphy, Linda S ; Tran, Minh-Ha</creator><creatorcontrib>Lin, David M ; Murphy, Linda S ; Tran, Minh-Ha</creatorcontrib><description>Abstract The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review—in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement—to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non–cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.</description><identifier>ISSN: 0887-7963</identifier><identifier>EISSN: 1532-9496</identifier><identifier>DOI: 10.1016/j.tmrv.2013.01.002</identifier><identifier>PMID: 23462530</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anticoagulants - adverse effects ; Blood Coagulation - drug effects ; Blood Coagulation Factors - adverse effects ; Blood Coagulation Factors - therapeutic use ; Cardiac Surgical Procedures - adverse effects ; Cardiac Surgical Procedures - methods ; Cardiac Surgical Procedures - statistics &amp; numerical data ; Fibrinogen - adverse effects ; Fibrinogen - therapeutic use ; Hematology, Oncology and Palliative Medicine ; Hemostatics - adverse effects ; Hemostatics - therapeutic use ; Humans ; Meta-Analysis as Topic ; Perioperative Care - methods ; Postoperative Hemorrhage - epidemiology ; Postoperative Hemorrhage - prevention &amp; control ; Treatment Outcome ; Warfarin - adverse effects</subject><ispartof>Transfusion medicine reviews, 2013-04, Vol.27 (2), p.91-104</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-c6fdfa68b2cd36ac88be663101ef192ce1022f6b684d7bd0e2eeea820158fb9b3</citedby><cites>FETCH-LOGICAL-c455t-c6fdfa68b2cd36ac88be663101ef192ce1022f6b684d7bd0e2eeea820158fb9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tmrv.2013.01.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23462530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, David M</creatorcontrib><creatorcontrib>Murphy, Linda S</creatorcontrib><creatorcontrib>Tran, Minh-Ha</creatorcontrib><title>Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review</title><title>Transfusion medicine reviews</title><addtitle>Transfus Med Rev</addtitle><description>Abstract The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review—in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement—to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non–cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.</description><subject>Anticoagulants - adverse effects</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation Factors - adverse effects</subject><subject>Blood Coagulation Factors - therapeutic use</subject><subject>Cardiac Surgical Procedures - adverse effects</subject><subject>Cardiac Surgical Procedures - methods</subject><subject>Cardiac Surgical Procedures - statistics &amp; numerical data</subject><subject>Fibrinogen - adverse effects</subject><subject>Fibrinogen - therapeutic use</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hemostatics - adverse effects</subject><subject>Hemostatics - therapeutic use</subject><subject>Humans</subject><subject>Meta-Analysis as Topic</subject><subject>Perioperative Care - methods</subject><subject>Postoperative Hemorrhage - epidemiology</subject><subject>Postoperative Hemorrhage - prevention &amp; control</subject><subject>Treatment Outcome</subject><subject>Warfarin - adverse effects</subject><issn>0887-7963</issn><issn>1532-9496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV9rFDEUxYModq1-AR8kj77MmD872YyIUJZWCwWLa59DkrnTZp1J1iSzut--GbYW9KFPF-4958D5XYTeUlJTQsWHbZ3HuK8ZobwmtCaEPUML2nBWtctWPEcLIuWqWrWCn6BXKW2LgEoiXqITxpeCNZws0HSTAIceX8eQ72IYjfN4HcbdAH_K9BZ8jjpDwtp3-MKZ6Hy4Bf_vrXjyHeBriC7soOzcHvAGcnb-9iM-w5tDyjCWtcXfYe_g92v0otdDgjcP8xTdXJz_WH-trr59uVyfXVV22TS5sqLvei2kYbbjQlspDQjBS3noacssUMJYL4yQy25lOgIMALQsQBrZm9bwU_T-mLuL4dcEKavRJQvDoD2EKSnKmVjxmUuRsqPUxpBShF7toht1PChK1IxbbdWMW824FaGquIrp3UP-ZEboHi1_-RbBp6MASsvSPKpkHRR0nYtgs-qCezr_8392OzjvrB5-wgHSNkzRF36KqsQUUZv54fO_aelECG_4PV5yqEM</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Lin, David M</creator><creator>Murphy, Linda S</creator><creator>Tran, Minh-Ha</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130401</creationdate><title>Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review</title><author>Lin, David M ; Murphy, Linda S ; Tran, Minh-Ha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-c6fdfa68b2cd36ac88be663101ef192ce1022f6b684d7bd0e2eeea820158fb9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anticoagulants - adverse effects</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation Factors - adverse effects</topic><topic>Blood Coagulation Factors - therapeutic use</topic><topic>Cardiac Surgical Procedures - adverse effects</topic><topic>Cardiac Surgical Procedures - methods</topic><topic>Cardiac Surgical Procedures - statistics &amp; numerical data</topic><topic>Fibrinogen - adverse effects</topic><topic>Fibrinogen - therapeutic use</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hemostatics - adverse effects</topic><topic>Hemostatics - therapeutic use</topic><topic>Humans</topic><topic>Meta-Analysis as Topic</topic><topic>Perioperative Care - methods</topic><topic>Postoperative Hemorrhage - epidemiology</topic><topic>Postoperative Hemorrhage - prevention &amp; control</topic><topic>Treatment Outcome</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, David M</creatorcontrib><creatorcontrib>Murphy, Linda S</creatorcontrib><creatorcontrib>Tran, Minh-Ha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion medicine reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, David M</au><au>Murphy, Linda S</au><au>Tran, Minh-Ha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review</atitle><jtitle>Transfusion medicine reviews</jtitle><addtitle>Transfus Med Rev</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>27</volume><issue>2</issue><spage>91</spage><epage>104</epage><pages>91-104</pages><issn>0887-7963</issn><eissn>1532-9496</eissn><abstract>Abstract The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review—in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement—to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non–cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23462530</pmid><doi>10.1016/j.tmrv.2013.01.002</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-7963
ispartof Transfusion medicine reviews, 2013-04, Vol.27 (2), p.91-104
issn 0887-7963
1532-9496
language eng
recordid cdi_proquest_miscellaneous_1326730021
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Anticoagulants - adverse effects
Blood Coagulation - drug effects
Blood Coagulation Factors - adverse effects
Blood Coagulation Factors - therapeutic use
Cardiac Surgical Procedures - adverse effects
Cardiac Surgical Procedures - methods
Cardiac Surgical Procedures - statistics & numerical data
Fibrinogen - adverse effects
Fibrinogen - therapeutic use
Hematology, Oncology and Palliative Medicine
Hemostatics - adverse effects
Hemostatics - therapeutic use
Humans
Meta-Analysis as Topic
Perioperative Care - methods
Postoperative Hemorrhage - epidemiology
Postoperative Hemorrhage - prevention & control
Treatment Outcome
Warfarin - adverse effects
title Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A06%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Prothrombin%20Complex%20Concentrates%20and%20Fibrinogen%20Concentrates%20in%20the%20Perioperative%20Setting:%20A%20Systematic%20Review&rft.jtitle=Transfusion%20medicine%20reviews&rft.au=Lin,%20David%20M&rft.date=2013-04-01&rft.volume=27&rft.issue=2&rft.spage=91&rft.epage=104&rft.pages=91-104&rft.issn=0887-7963&rft.eissn=1532-9496&rft_id=info:doi/10.1016/j.tmrv.2013.01.002&rft_dat=%3Cproquest_cross%3E1326730021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1326730021&rft_id=info:pmid/23462530&rft_els_id=1_s2_0_S0887796313000035&rfr_iscdi=true